Results 51 to 60 of about 73,664 (299)
Circulating histones as clinical biomarkers in critically ill conditions
FEBS Letters, EarlyView.Circulating histones are emerging as promising biomarkers in critical illness due to their diagnostic, prognostic, and therapeutic potential. Detection methods such as ELISA and mass spectrometry provide reliable approaches for quantifying histone levels in plasma samples.
José Luis García‐Gimenez +17 more
wiley +1 more source
Application of Immuno-PET in Antibody–Drug Conjugate Development
Molecular Imaging, 2018 Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective ...
Kendra S. Carmon PhD, Ali Azhdarinia PhD
doaj +1 more source
Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). [PDF]
PLoS ONE, 2015 The humanized monoclonal antibody-drug conjugate trastuzumab emtansine (T-DM1, Kadcyla) has been approved by the U.S. FDA to treat human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Yuan-Chiang Chung +4 more
doaj +1 more source
Progresses in research and development of antibody-drug conjugate
生物医学转化, 2021 Through referring to the literature and related databases, the research process of antibodyconjugated drugs was reviewed, and the key elements of ADC were summarized.
Wu Gang +6 more
doaj +1 more source
Aptamer-based therapeutics and their potential in radiopharmaceutical design [PDF]
, 2007 Aptamers, short, single stranded oligonucleotide entities, have been developed in the past 15 years against a plethora of targets and for a variety of applications.
Ferreira, Catia S. M. +1 more
core +3 more sources
FEBS Letters, EarlyView.Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu +17 more
wiley +1 more source
Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
Biomolecules, 2020 The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or stimulate its activity is the basis for the rapid growth and development of the therapeutic antibody field.
Hyunbo Shim
doaj +1 more source
mAbs, 2021 This study describes the characterization of conjugation sites for a random, lysine conjugated 2-iminothiolane (2-IT) based antibody-drug-conjugate synthesized from an IgG1 antibody and a duocarmycin analog-based payload-linker. Of the 80 putative lysine
Difei Qiu +4 more
doaj +1 more source
Antibody drug conjugates in the clinic
Bioengineering & Translational MedicineAbstractAntibody‐drug conjugates (ADCs), chemotherapeutic agents conjugated to an antibody to enhance their targeted delivery to tumors, represent a significant advancement in cancer therapy. ADCs combine the precise targeting capabilities of antibodies and the potent cell‐killing effects of chemotherapy, allowing for enhanced cytotoxicity to tumors ...
Edidiong Udofa +3 more
openaire +3 more sources
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements [PDF]
, 2009 IT-101, a cyclodextrin polymer-based nanoparticle containing camptothecin, is in clinical development for the treatment of cancer. Multiorgan pharmacokinetics and accumulation in tumor tissue of IT-101 is investigated by using PET.
Alley +33 more
core +3 more sources